Xiuning Le, FLAURA2

Xiuning Le Highlights ctDNA EGFR Mutation Insights from RAMOSE Trial at AACR25

Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on X:

“Dr. Simon Heek presented ‘Association of baseline ctDNA EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinibversus osimertinibin EGFR+ Lung Cancer.’
  • Baseline assessment of EGFR mutations from ctDNA is feasible with short turn-around time
  • ctDNA EGFR VAF >0.5% is associated with significantly shorter PFS
  • Detectable EGFR mutations from ctDNA at baseline was associated with numerically shorter PFS
  • No deaths occurred in patients without detectable EGFRmutations in ctDNA
  • We will report on-treatment ctDNA association and radiomics translational work in future conferences”Xiuning Le Highlights ctDNA EGFR Mutation Insights from RAMOSE Trial at AACR25

More posts featuring AACR25.

AACR25 cancer EGFR-mutation Lung cancer OncoDaily Oncology RAMOSE trial Simon Heek Xiuning Le